The Best of Oncology West, chaired by Dr. Daniel Heng and Dr. Sharlene Gill, will consist of the most influential oncologists from across Western Canada. This hybrid event will highlight the top 3-4 most clinically relevant achievements for 2022 across many tumour sites with a focus on Western faculty and audience.

  1. Discussion of the pivotal oncology trials presented in the different disease sites
  2. Review of the current standard of care for key malignancies
  3. Discussion of the current controversies in the management of specific cancers

In Person & Free Virtual Registration Options Below:

For the safety of our registrants and the vulnerable patient population they serve, we strongly encourage the use of masks by all attendees. This is also a reminder that all attendees must be fully vaccinated against COVID-19 by the time of the event.

EARLY BIRD PRICING ENDS DECEMBER 12th

Book Event

Virtual FREE
Available Tickets: 79
The Virtual ticket is sold out. You can try another ticket or another date.
In person - Physicians CAD $75

The Westin Bayshore, Vancouver

Available Tickets: 79
The In person - Physicians ticket is sold out. You can try another ticket or another date.
In person - Nurses, Pharmacists, Other Allied Healthcare Professionals CAD $45

The Westin Bayshore, Vancouver

Available Tickets: 79
The In person - Nurses, Pharmacists, Other Allied Healthcare Professionals ticket is sold out. You can try another ticket or another date.
In person - Students and Residents CAD $21

The Westin Bayshore, Vancouver

Available Tickets: 79
The In person - Students and Residents ticket is sold out. You can try another ticket or another date.

Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at kelly@oncologyeducation.ca for registration and sponsorship opportunities.

Join Us Live In Person
at the
The Westin Bayshore, Vancouver

Scientific Agenda

Sessions are listed in Pacific Time

Local Time

  • Timezone: America/New_York
  • Date: Friday, January 13, 2023
  • Time: 11:00 am - 7:00 pm

7:00 am – 8:00 am

Registration and Breakfast Buffet

8:00 am – 8:45 am

Breakfast Symposium

8:45 am – 8:55 am

Welcome Address – Dr. Daniel Heng & Dr. Sharlene Gill

8:55 am – 9:25 am

Prostate and Non-Prostate GU Cancer – Dr. Vishal Navani

9:25 am – 9:50 am

Colorectal GI Cancer – Dr. Jonathan Loree

9:50 am – 10:15 am

Non-Colorectal GI Cancer – Dr. Sharlene Gill

10:15 am – 10:35 am

Networking Break & Sponsor Exhibits

10:35 am – 11:00 am

Gynecological Cancers – Dr. Anna Tinker

11:00am – 11:25am

Theranostics 101 – Dr. Patrick Martineau

11:25 am – 11:50 am

Lung Cancer – Dr. Krista Noonan

11:50 am – 12:10 pm

TBA

12:10 pm – 12:40 pm

Lunch Break and Buffet

12:40 pm – 1:25 pm

Lunch Symposium

1:25 pm – 1:50 pm

Special Session: Choosing Wisely – Dr. Safiya Karim

1:50 pm – 2:15 pm

An Approach to Sarcoma – Dr. Alannah Smrke

2:15 pm – 2:35 pm

Networking Break & Sponsor Exhibits

2:35 pm – 3:00 pm

Hematologic Malignancies – Dr. Christopher Venner

3:00 pm – 3:25 pm

Melanoma – Dr. Jose Monzon

3:25 pm – 3:50 pm

Breast Cancer – Dr. Nathalie LeVasseur

3:50 pm – 4:00 pm

Closing Remarks – Dr. Daniel Heng & Dr. Sharlene Gill

personAbout the Faculty

Suneil Khanna

Dr. Daniel Heng

Conference Chair

Dr. Daniel Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer Agency in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the International mRCC Database Consortium (IMDC) which has created and validated the IMDC criteria (a.k.a. Heng Criteria) for prognostication in metastatic renal cell carcinoma patients. He is also the Chair of the Genitourinary Tumor Group in Calgary and Medical Leader for the Clinical Research Unit at the TBCC. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies.

Dr. Sharlene Gill

Dr. Sharlene Gill

Conference Chair

Dr. Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer –Vancouver. She received a Bachelor’s of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 100peer-reviewed publications and book chapters to her credit. Dr. Gill currently serves as the Chair of the Canadian Clinical Trials Group (CCTG)GI Disease Site Committee, and is President-Elect for the Canadian Association of Medical Oncologists.

Sponsorship

GOLD

Astellas Logo

SILVER

BMS Logo
Ipsen Logo